About the Company
rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RZLT News
Rezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying
Rezolute, Inc. ( NASDAQ:RZLT ) insiders who bought shares over the past year were rewarded handsomely last week.
3 Stocks Insiders Are Buying That Analysts Love
It’s one thing for insiders to buy a stock, but it is something else if the market is also on board with the investment.
$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their ...
$17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed higher by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their ...
Loading the latest forecasts...